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Psoriatic arthritis
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Abstract

Objective The Psoriatic Arthritis Long-term Assessment of
Clinical Efficacy (PALACE) clinical trial programme findings
demonstrated that apremilast, an oral phosphodiesterase
4 inhibitor, is effective for treating psoriatic arthritis (PsA).
Enthesitis and dactylitis are difficult-to-treat features
of PsA leading to disability and affecting quality of life.
PALACE 1, 2 and 3 data were pooled to assess the efficacy
of apremilast on enthesitis and dactylitis outcomes in
patients with these conditions at baseline.
Methods Patients with enthesitis (n=945) or dactylitis
(n=633) at baseline were analysed after receiving doubleblind treatment with placebo, apremilast 30 mg two
times per day or apremilast 20 mg two times per day up
to 52 weeks and continuing up to 5 years. Data were
analysed through 156 weeks. Enthesitis was evaluated
by Maastricht Ankylosing Spondylitis Enthesitis Score
(MASES) and dactylitis via dactylitis count.
Results At week 24, patients receiving apremilast 30 mg
two times per day demonstrated a significantly greater
mean change in enthesitis (−1.3 vs −0.9; p<0.05) and
dactylitis (−1.8 vs −1.3; p<0.01) vs placebo. Patients
in the 30 mg dose group showed significantly greater
mean (−23.6% vs −7.0%; p<0.05) and median (−50.0%
vs −21.1%; p<0.05) per cent changes in MASES; mean
and median per cent changes in dactylitis count were
numerically, but not significantly, different for either
apremilast dose in patients with dactylitis. In the patient
population remaining on apremilast, observed mean and
median improvements in both conditions were sustained
through 156 weeks.
Conclusion Apremilast is effective for the treatment
of active PsA, including improvements in enthesitis and
dactylitis up to 3 years.
Trial registration numbers NCT01172938,
NCT01212757 and NCT01212770.

Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease that is remarkably diverse in presentation and course and is characterised by

Key messages

What is already known about this subject?
►► Enthesitis and dactylitis are core features of psoriat-

ic arthritis (PsA) that are difficult to treat and impact
the overall severity and burden of disease.
►► Apremilast, an oral small molecule that inhibits
phosphodiesterase 4, has been shown to be effective in the treatment of PsA in the Psoriatic Arthritis
Long-term Assessment of Clinical Efficacy (PALACE)
clinical trial programme; however, the individual
studies were not designed to obtain meaningful conclusions for patients with enthesitis and/or dactylitis.

What does this study add?
►► The findings of this pooled analysis of data from

the PALACE studies provide long-term data demonstrating the effectiveness of apremilast in improving
enthesitis and dactylitis in patients with active PsA.

How might this impact on clinical practice?
►► Apremilast provides an effective treatment option for

the long-term treatment of enthesitis and dactylitis
in patients with active PsA.

the presence of peripheral arthritis, psoriasis,
enthesitis, dactylitis and spondylitis as well
as skin and nail manifestations.1–3 Enthesitis
and dactylitis are distinguishing features of
PsA that may be associated with more severe
disease; both conditions can be difficult to
treat, lead to disability and negatively impact
quality of life.2 4–8 Current therapeutic options
for PsA include systemic therapy with conventional disease-modifying antirheumatic drugs
(DMARDs) or biological agents; however, to
date, there is little evidence of the efficacy
of conventional DMARDs in enthesitis or
dactylitis in PsA.9
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Apremilast is an oral phosphodiesterase 4 inhibitor
that helps regulate the aberrant immune response in
PsA that causes joint symptoms, enthesitis, dactylitis,
systemic inflammation and skin disease.1 10 The efficacy
and safety of apremilast in PsA are being evaluated in the
Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme. The PALACE
1, 2 and 3 studies are assessing the efficacy and safety
of apremilast in patients with active PsA despite prior
conventional DMARDs and/or biological therapy. This
programme has collected a large dataset for patients
with PsA, allowing for comprehensive analyses of many
aspects of treatment outcomes. Results from all three
PALACE studies demonstrated that apremilast is effective in reducing the signs and symptoms of PsA and in
improving physical function.11–14
Although the impact of apremilast treatment on
enthesitis and dactylitis was evaluated in each of the
PALACE studies, the presence of these conditions was
not required for inclusion, and the studies were not
specifically designed to obtain meaningful conclusions
for patients with enthesitis and/or dactylitis. Therefore,
to assess short-term and long-term outcomes in a broad
population of patients with enthesitis and/or dactylitis
who entered PALACE 1, 2 and 3, a pooled analysis of data
from these patients in all three studies was conducted
to evaluate the therapeutic benefit of apremilast for
enthesitis and dactylitis over 156 weeks.
Methods
Study design
PALACE 1, 2 and 3 (NCT01172938, NCT01212757 and
NCT01212770) are phase III, multicentre, randomised,
double-blind, placebo-controlled clinical trials with
similar designs, which were previously described in
detail.11–14 Briefly, patients were randomised (1:1:1) to
receive placebo, apremilast 30 mg two times per day or
apremilast 20 mg two times per day, stratified by baseline DMARD use (yes/no) and, in PALACE 3 only, by
baseline psoriasis involvement of the body surface area
(<3%/≥3%; online supplementary figure 1). Patients
whose swollen and tender joint counts had not improved
by ≥20% at week 16 were considered non-responders and
continued on their initial apremilast dose or, if initially
randomised to placebo, were randomised (1:1) to receive
apremilast 30 mg two times per day or 20 mg two times
per day (early escape). At week 24, all remaining patients
on placebo were switched to apremilast 30 mg or 20 mg
two times per day. On completion of the 52 week, doubleblind period, patients were eligible to enter a long-term
treatment phase for a total follow-up of up to 5 years.
Study population
All patients provided written informed consent prior
to study initiation. Detailed inclusion and exclusion
criteria for the PALACE studies have been published
elsewhere.11 13 14 Briefly, adult patients required a
2

diagnosis of PsA for ≥6 months, met the Classification
Criteria for Psoriatic Arthritis (CASPAR) at study entry
and were required to have three or more swollen joints
and three or more tender joints at baseline. All patients
were required to have had current or prior therapy with
DMARDs and/or biological agents; however, they were
ineligible for study inclusion if they experienced therapeutic failure of more than three DMARDs or biologicals or more than one tumour necrosis factor blocker.
In addition, one or more plaque psoriasis lesions that
were ≥2 cm was required in PALACE 3. The focus of the
current analysis is patients who had enthesitis or dactylitis
at baseline. Limited analyses were conducted in patients
without enthesitis or dactylitis at baseline to examine the
development of these manifestations during 24 weeks.
Concomitant therapy of any combination of methotrexate (≤25 mg/week), leflunomide (≤20 mg/day),
sulfasalazine (≤2 g/day) with a stable dose for at least
16 weeks prior to screening was permitted during the
study, with one DMARD dose reduction allowed between
weeks 24 and 52. Stable doses of non-steroidal anti-inflammatory drugs for ≥2 weeks or oral corticosteroids
(prednisone ≤10 mg or equivalent) for ≥1 month prior
to screening were allowed.
Efficacy assessments
Enthesitis and dactylitis were clinically evaluated at baseline and at weeks 16, 24, 52, 65, 78, 91, 104, 117, 130, 143
and 156 (or at early termination/withdrawal). The assessments of enthesitis and dactylitis in PsA were proven to
be reliable in the INSPIRE study.15
Enthesitis in the current analysis was evaluated in
patients who had enthesitis at baseline, defined as a Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
>0. The MASES determines the presence or absence of
pain at 13 select entheses/tendon insertions,16 with scores
ranging from 0 to 13. Enthesitis outcomes included the
change and per cent change in MASES from baseline and
achievement of a MASES of 0 (no pain at any assessed
entheses).
Dactylitis was evaluated in patients with a dactylitis
count >0 at baseline, reflecting the presence (score=1) or
absence (score=0) of dactylitis in each of the 20 digits (the
possible dactylitis count ranges from 0 to 20). Dactylitis
outcomes included the change and per cent change
from baseline in dactylitis count and achievement of a
dactylitis count of 0, indicating the absence of dactylitis
on all 20 digits.
Statistical analysis
Data from PALACE 1, 2 and 3 were pooled in a prespecified analysis, permitting a robust analysis of data for all
randomised patients with pre-existing enthesitis (baseline MASES>0) and/or dactylitis (baseline dactylitis
count >0) who received one or more doses of study medication. Changes and per cent changes from baseline in
MASES and dactylitis count at week 24 were prespecified
and analysed using an analysis of covariance model with
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treatment, baseline DMARD use (yes/no) and study as
factors and the baseline value as a covariate. Per cent
changes from baseline were also analysed using rank
transformation, with the same analysis model. Missing
values were handled using the last-observation-carried-forward (LOCF) methodology. Specifically, for
patients who entered early escape at week 16, the week 16
value was carried forward to week 24; for other patients,
the last postbaseline value was carried forward if the week
24 value was missing. Analyses at week 52 were prespecified and analyses at weeks 104 and 156 were posthoc; all
long-term analyses are based on data as observed. Data
from all patients with enthesitis or dactylitis at baseline
were analysed descriptively through week 156, regardless
of when patients started treatment with apremilast (baseline, week 16 or week 24).
Results
Patient characteristics
Across PALACE 1, 2 and 3, 63.3% (945/1493) of patients
had enthesitis and 42.4% (633/1493) had dactylitis at
baseline and were included in the current analysis. Baseline patient demographics, disease characteristics and
prior and concurrent therapy were comparable across
treatment groups (table 1). Baseline mean MASES
(range 4.5–4.8) and dactylitis counts (range 3.2–3.4)
were also similar across treatment groups among patients
with enthesitis and dactylitis, respectively.
Efficacy results: enthesitis
At week 24, patients treated with apremilast 30 mg
two times per day demonstrated a significantly greater
mean change from baseline in enthesitis compared with
placebo (p=0.02) (table 2). Moreover, apremilast 30 mg
two times per day resulted in significantly greater mean
and median per cent changes in MASES from baseline
compared with placebo (table 2). Among patients treated
with either apremilast 30 mg twice daily or 20 mg twice
daily, numerically greater improvements in enthesitis and
in proportions of patients achieving a MASES of 0 were
observed compared with placebo at week 24 (table 2). In
the population of patients continuing apremilast 30 mg
two times per day or 20 mg two times per day through
3 years, mean and median improvements in MASES
were sustained. Specifically, at week 156, mean changes
from baseline were −2.7 (30 mg two times per day) and
−2.8 (20 mg two times per day) (table 2). Mean per cent
changes from baseline were −65.2% (30 mg two times per
day) and −57.6% (20 mg two times per day; figure 1A)
and median per cent changes were −100% for both treatment groups (table 2). At week 156, 55.0% of patients
treated with apremilast 30 mg two times per day and
55.1% treated with apremilast 20 mg two times per day
achieved a MASES of 0 (figure 1B). When looking at the
development of enthesitis over time in patients with a
MASES of 0 at baseline, almost twice as many placebo
patients (32.7%) with a MASES of 0 at baseline developed
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enthesitis at week 24 than patients treated with apremilast 30 mg two times per day (18.4%) or 20 mg two times
per day (18.2%).
Efficacy results: dactylitis
At week 24, mean dactylitis count was significantly
improved from baseline in patients treated with apremilast 30 mg two times per day compared with placebo
(p≤0.01). Mean and median per cent changes from
baseline were not significantly different in either dose
group compared with placebo; however, the median
per cent change from baseline in the 30 mg dose group
trended toward statistical significance vs placebo (p=0.06;
table 3). The difference in the proportion of patients
achieving a dactylitis count of 0 was not statistically significant (table 3).
In the population of patients continuing apremilast
treatment through 3 years, mean and median improvements in dactylitis count were sustained (figure 2A;
table 3). Specifically, at week 156, mean changes from
baseline were −3.0 (30 mg two times per day) and −2.4
(20 mg two times per day). Mean per cent changes in
dactylitis count were −83.6% (30 mg two times per day)
and −73.4% (20 mg two times per day; figure 2A) and
median per cent changes from baseline at week 156 were
−100.0% for both dose groups (table 3). At week 156,
79.6% of patients treated with apremilast 30 mg two times
per day and 73.9% treated with apremilast 20 mg two
times per day achieved a dactylitis count of 0 (figure 2B).
Among patients with a dactylitis count of 0 at baseline,
approximately twofold as many patients receiving placebo
(15.8%) developed dactylitis versus patients treated with
apremilast 30 mg two times per day (8.3%) or apremilast
20 mg two times per day (7.0%) at week 24.
Discussion
When assessing new therapies for the treatment of PsA,
it is important to understand the impact treatment
has on hallmark features of PsA such as enthesitis and
dactylitis.9 17–21 These conditions often occur in the lower
extremities and may cause tenderness or pain while
standing and walking4 5 7 as well as limit the ability to
hold or grasp objects and affect fine motor function.4 22
Overall, they are associated with impaired function, may
negatively impact quality of life and are difficult to treat
using conventional treatments.4–8 Both enthesitis and
dactylitis also significantly contribute to the perceived
burden of disease among patients with PsA.23 Dactylitis is
actually considered a marker of PsA disease severity.7 24 25
It is also noteworthy that there is little evidence suggesting
conventional DMARDs are effective in treating either
enthesitis or dactylitis.9
The results from our pooled analysis of patients with
enthesitis and/or dactylitis at baseline in the PALACE
1, 2 and 3 studies showed that apremilast is effective in
reducing the severity of both conditions in the population of patients remaining on apremilast through
3

4

 Sulfasalazine (mean dose, 2.03 g/day*;
  1.94 g/day†)
31 (10.0)
Corticosteroid use (mean dose, 6.29 mg/ 29 (9.3)
day*; 6.27 mg/day†), n (%)

31 (9.5)
38 (11.6)

19 (5.8)

172 (52.6)

206 (63.0)

28 (8.6)

20 (6.4)

7.9

 Leflunomide (mean dose, 17.9 mg/
day*; 17.7 mg/day†)

7.8

Psoriasis body surface area, mean, %

8.4 (7.9)

4.9 (1.0)

172 (55.3)

8.8 (9.7)

PASI score‡ (0–72), mean

201 (64.6)

4.8 (1.1)

DAS-28 (CRP), mean (SD)

1.00 (1.5)

1.3 (0.62)

 Methotrexate (mean dose, 15.3 mg/
week*; 15.2 mg/week†)

1.10 (1.6)

CRP (normal range: 0–0.499), mean, mg/
dL

Concomitant conventional DMARD use,
n (%)

1.3 (0.60)

HAQ-DI score (0–3), mean (SD)

3.0 (1, 19)

3.7 (3.6)

70 (21.4)

2.0 (1, 20)

 Median (minimum, maximum)

29 (9.3)

3.4 (3.5)

Dactylitis count† (0–20), mean (SD)

4.0 (1, 13)

62 (19.9)

4.0 (1, 13)

 Median (minimum, maximum)

4.5 (3.2)

25.1 (15.7)

Prior biological failures, n (%)

4.8 (3.3)

MASES* (0–13), mean (SD)

Prior use of biologicals, n (%)

22.6 (15.9)

Tender joint count (0–78), mean (SD)

12.3 (8.5)

252 (77.1)

11.6 (8.3)

Swollen joint count (0–76), mean (SD)

17.6

7.4

30.1

50.8
196 (59.9)

Prior use of conventional DMARDs only,
n (%)
242 (77.8)

7.3
18.0

Duration of psoriasis, mean, years

30.5

Body mass index, mean, kg/m2

Duration of PsA, mean, years

50.2
174 (55.9)

31 (10.1)
59 (19.2)

20 (6.5)

158 (51.5)

192 (62.5)

28 (9.1)

81 (26.4)

223 (72.6)

7.4

7.5 (7.1)

4.8 (1.0)

0.94 (1.3)

1.3 (0.61)

2.0 (1, 20)

3.8 (3.9)

4.0 (1, 13)

4.6 (3.3)

24.9 (17.9)

12.4 (9.3)

17.9

7.1

30.4

49.7
175 (57.0)

20 mg two times per
day (n=307)

19 (9.3)
19 (9.3)

15 (7.3)

118 (57.6)

138 (67.3)

20 (9.8)

45 (22.0)

157 (76.6)

8.4

8.1 (7.7)

4.8 (1.1)

1.17 (1.5)

1.3 (0.62)

2.0 (1, 20)

3.2 (3.3)

4.0 (1, 13)

4.8 (3.4)

22.4 (15.7)

13.3 (8.7)

17.1

7.2

30.6

49.2
106 (51.7)

Placebo
(n=205)

22 (10.0)
23 (10.4)

19 (8.6)

121 (54.8)

145 (65.6)

14 (6.3)

41 (18.6)

178 (80.5)

8.2

8.5 (8.6)

4.9 (1.0)

1.21 (1.7)

1.3 (0.64)

2.0 (1, 19)

3.3 (3.3)

4.0 (1, 13)

4.1 (2.7)

23.9 (15.0)

14.2 (9.8)

17.3

7.7

29.5

49.5
105 (47.5)

30 mg two times
per day (n=221)

22 (10.6)
35 (16.9)

15 (7.2)

127 (61.4)

146 (70.5)

10 (4.8)

40 (19.3)

167 (80.7)

8.5

7.8 (6.6)

4.7 (1.2)

1.05 (1.3)

1.2 (0.68)

2.0 (1, 20)

3.4 (3.4)

4.0 (1,13)

4.8 (3.4)

24.7 (18.5)

14.0 (10.2)

17.6

8.0

29.6

47.8
101 (48.8)

Continued

20 mg two times per
day (n=207)

Apremilast

30 mg two times per
day (n=327)

Apremilast
Placebo
(n=311)

Patients with dactylitis at baseline (n=633)

Patients with enthesitis at baseline (n=945)

Baseline demographics and disease characteristics, by treatment group in patients with enthesitis or dactylitis at baseline

Age, mean, years
Females, n (%)

Table 1
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The n reflects the number of randomised patients who received at least one dose of study medication; actual number of patients available for each parameter may vary.
*Examined among patients who had enthesitis at baseline.
†Examined among patients who had dactylitis at baseline.
‡Patients with baseline psoriasis involvement of the body surface area of ≥3%.
§All converted to oral prednisone dose.
CRP, C reactive protein; DAS-28, 28-joint count Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; MASES,
Maastricht Ankylosing Spondylitis Enthesitis Score; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.

154 (74.4)
162 (73.3)
137 (66.8)
221 (72.0)

20 mg two times per
day (n=307)
30 mg two times per
day (n=327)
Placebo
(n=311)

233 (71.3)

20 mg two times per
day (n=207)
30 mg two times
per day (n=221)

Apremilast
Apremilast

Placebo
(n=205)

Patients with dactylitis at baseline (n=633)
Patients with enthesitis at baseline (n=945)

218 (70.1)
Baseline NSAID use, n (%)

Table 1   Continued

Psoriatic arthritis
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3 years of treatment. At baseline, nearly two-thirds of
enrolled patients had enthesitis and approximately half
had dactylitis in one or more digits. By week 24, statistically significant improvements in enthesitis (mean,
mean per cent and median per cent changes) were
observed after treatment with apremilast 30 mg two
times per day. Although mean and median per cent
improvements in dactylitis were not significant, apremilast 30 mg two times per day showed a strong trend
towards improvement versus placebo (median per cent
change, −79.3% vs −66.7%; p=0.06), and the mean
change in dactylitis count at week 24 was significant
and sustained through 156 weeks in the population of
patients continuing treatment. Despite the pooling of
the three studies, the number of patients in the analysis
is relatively small.
It is also noteworthy that patients who were treated
with apremilast showed improvements in enthesitis and
dactylitis already present at baseline and demonstrated
lower rates of onset of these conditions during the study.
Specifically, among patients with a MASES of 0 at baseline, about twice as many patients receiving placebo
developed enthesitis versus patients treated with apremilast 30 mg two times per day (32.7% vs 18.4%) at week 24.
Among the subgroup of patients who entered early escape
(failed to achieve ≥20% improvement in swollen and
tender joint counts at week 16), a comparable number of
placebo versus apremilast patients developed enthesitis
(39.3% vs 41.5%). Among patients with a dactylitis count
of 0 at baseline, almost twofold as many patients receiving
placebo developed dactylitis versus patients treated with
apremilast 30 mg two times per day (15.8% vs 8.3%) at
week 24. Similarly, of those patients who entered early
escape, nearly twice as many patients receiving placebo
developed dactylitis versus patients treated with apremilast (21.5% vs 12.6%).
Previous analyses of PALACE data from weeks 16 and 24
did not detect consistent, significantly greater improvements in enthesitis or dactylitis with apremilast versus
placebo in all studies.11 14 This might be partially due to
insufficient numbers of patients with these conditions at
baseline to yield adequate power to detect differences
between treatment groups. We believe that this pooled
analysis helps to address these challenges, yielding
greater power to detect changes in enthesitis or dactylitis
than in the individual PALACE studies; however, this still
may not be enough.
This study had several limitations. First, long-term
results were posthoc analyses of mean and median
changes in a population of patients continuing treatment in the PALACE studies, which were not originally
designed nor powered to investigate outcomes relating
to enthesitis and dactylitis. Second, in recognising the
heterogeneity in the instruments used to evaluate and
interpret enthesitis and dactylitis measures,20 26 we
understand that the MASES was designed for patients
with ankylosing spondylitis where sites of interest are
more central and may not be ideal for evaluating the
5

6
Apremilast

−1.3‡

−0.9

−7.0

Mean per cent
change from
baseline

−40.0
84/307 (27.4)

−19.3

−1.2

4.6

20 mg two
times per day
(n=298)

−66.7
142/377 (37.7)

−43.5

−2.0

4.4

30 mg two
times per day
(n=377)

Apremilast

Week 52

−66.7
134/326 (41.1)

−42.2

−2.2

4.5

20 mg two
times per day
(n=326)

−85.7
147/302 (48.7)

−57.5

−2.6

4.3

30 mg two
times per day
(n=302)

Apremilast

Week 104

−100.0
135/261 (51.7)

−55.2

−2.6

4.6

20 mg two
times per day
(n=261)

−100.0
153/278 (55.0)

−65.2

−2.7

4.2

30 mg two
times per
day (n=278)

Apremilast

Week 156

−100.0
125/227 (55.1)

−57.6

−2.8

4.4

20 mg two
times per day
(n=227)

*The n at week 24 represents patients with a baseline value >0 and ≥1 postbaseline value at or before week 24. Data as observed for weeks 52, 104 and 156; the n represents the number of
patients taking apremilast, regardless of when treatment started (baseline, week 16 or week 24), with a baseline value >0 and a value at the specific visit.
†MASES ranges from 0 to 13, with 0 indicating no pain at any assessed entheses and 13 indicating pain at all assessed entheses.
‡P<0.05 vs placebo.
§The per cent change noted occurred in >50% of patients.
¶Patients who did not have sufficient data (observed or imputed) for a definitive determination of response status at week 24 are counted as non-responders.
LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.

Median per cent
change from
baseline§
−21.1
−50.0‡
Score of 0¶, n/m (%) 70/311 (22.5) 90/327 (27.5)

−23.6‡

4.4

4.8

Baseline, mean
Mean change from
baseline

30 mg two
times per day
(n=315)

(n=302)

Placebo

Week 24

Enthesitis at week 24 (LOCF) and weeks 52, 104 and 156 (as observed)*

MASES†

Table 2
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Figure 1 (A) Mean per cent change in MASES up to week 156 and (B) patients achieving a MASES of 0 up to week 156.
Data as observed in patients with pre-existing enthesitis. Analyses include all patient data, including the placebo-controlled
period, regardless of when patients started taking apremilast (baseline, week 16 or week 24). MASES, Maastricht Ankylosing
Spondylitis Enthesitis Score; n/m, number of responders/number of patients with sufficient data for evaluation.

more characteristically peripheral sites of interest in
PsA.27 In future studies, scales such as the Spondyloarthritis Research Consortium of Canada enthesitis index
Gladman DD, et al. RMD Open 2018;4:e000669. doi:10.1136/rmdopen-2018-000669

or Leeds Enthesitis Index that evaluate peripheral
enthesitis sites may be more appropriate for patients
with PsA.15 27 Third, this study did not assess the impact
7

8
−79.3

−48.6

−1.8‡

3.2

168/249 (67.5)

−100.0

−67.9

−2.5

3.4

150/225 (66.7)

−100.0

−70.2

−2.3

3.3

20 mg two
times per day
(n=225)

Week 104

155/200 (77.5)

−100.0

−80.0

−2.9

3.4

30 mg t two
times per day
(n=200)

Apremilast

132/182 (72.5)

−100.0

−75.6

−2.4

3.2

20 mg two
times per day
(n=182)

Week 156

144/181 (79.6)

−100.0

−83.6

−3.0

3.4

30 mg two
times per day
(n=181)

Apremilast

116/157 (73.9)

−100.0

−73.4

−2.4

3.0

20 mg two
times per day
(n=157)

*The n at week 24 represents patients with a baseline value >0 and ≥1 postbaseline value at or before week 24. Data as observed for weeks 52, 104 and 156. The n represents the number of
patients taking apremilast, regardless of when treatment started (baseline, week 16 or week 24), with a baseline value >0 and a value at the specific visit.
†Dactylitis count is the sum of all scores for each of the 20 digits, with each digit scored as 0=absence or 1=presence of dactylitis.
‡P<0.01 vs placebo.
§The per cent change noted occurred in >50% of patients.
¶Patients who did not have sufficient data (observed or imputed) for a definitive determination of response status at week 24 are counted as non-responders.
LOCF, last observation carried forward.

95/207 (45.9)

−75.0

−43.2

−1.6

3.4

30 mg two
times per day
(n=249)

20 mg two
times per day
(n=202)

30 mg two
times per day
(n=214)

Week 52
Apremilast

Apremilast

80/205 (39.0) 102/221 (46.2)

−66.7

−38.2

Median per cent
change from
baseline§
Dactylitis count of
0¶, n/m (%)

−1.3

Mean per cent
change from
baseline

3.3

Baseline, mean
Mean change from
baseline

Placebo
(n=194)

Week 24

Dactylitis at week 24 (LOCF) and weeks 52, 104 and 156 (as observed)*

Dactylitis count†

Table 3

RMD Open
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Figure 2 (A) Mean per cent change in dactylitis up to week 156 and (B) patients achieving a dactylitis count of 0 up to week
156. Data as observed in patients with pre-existing dactylitis. Analyses include all patient data, including the placebo-controlled
period, regardless of when patients started taking apremilast (baseline, week 16 or week 24). n/m, number of responders/
number of patients with sufficient data for evaluation.
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of apremilast on patients with acute versus chronic
dactylitis; rather, the analysis took a binary approach to
determine whether the condition was merely present
or absent. The mean dactylitis count at baseline was
associated with a limited dynamic range (3.2–3.4),
which may have limited our ability to detect differences
between apremilast and placebo. This contrasts with
methods based on the grading of dactylitis severity for
each digit, as used in the GO-REVEAL study with golimumab (0=no dactylitis; 3=severe dactylitis; range 0–60)28
or based on the size and tenderness of each digit with
dactylitis (Leeds Dactylitis Instrument),29 as used in the
RAPID-PsA study.30 These methods may be associated
with greater sensitivity to detect changes between active
therapies and placebo.
Our analysis may have also been limited by the fact
that improvements observed in placebo patients in the
initial PALACE studies were somewhat greater than those
observed in studies with other agents,31 32 potentially
reducing the observed therapeutic effect of apremilast.
The observed level of improvement in enthesitis and
dactylitis among placebo patients was unexpected and
not explained by baseline differences between groups in
symptom severity, which was generally similar between
treatment groups. The ability to detect enthesitis and
dactylitis improvement following treatment may have
been differentially impacted by the natural course and
variation of the symptoms evaluated. For example,
improvements among patients with enthesitis receiving
placebo may be partially explained by previous evidence,
suggesting this condition may naturally improve over
time, regardless of treatment.6 8
In conclusion, enthesitis and dactylitis are core
features of PsA that have an important impact on overall
severity and burden of disease. In this analysis of patients
continuing apremilast treatment, we observed improvements in the difficult-to-treat manifestations of PsA,
enthesitis and dactylitis, up to 3 years.
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